The aim was to evaluate the feasibility of administering therapeutic amounts of medications for the treatment of Alzheimer's Disease (AD) and Parkinson's Disease (PD) across the skin using innovative formulations and novel transdermal delivery technologies. In addition to the direct impact on patient health and quality of life, both conditions exact a considerable toll on caregivers who must cope with patients as their disease progresses and renders them increasingly dependent. Oral administration of therapeutics may become problematic; thus, it is desirable to have methods that are “independent” of the patient's condition. Transdermal delivery would address this need; however, the skin's excellent barrier function restricts the number of molecules that can be delivered by this route. As a result, there has been considerable effort to develop new techniques to improve drug delivery. The results of the project demonstrated that transdermal iontophoresis was indeed capable of achieving therapeutic delivery of drugs for both AD and PD.